JP Patent

JP7153719B2 — ６－（２－ヒドロキシ－２－メチルプロポキシ）－４－（６－（６－（（６－メトキシピリジン－３－イル）メチル）－３，６－ジアザビシクロ［３．１．１］ヘプタン－３－イル）ピリジン－３－イル）ピラゾロ［１，５－ａ］ピリジン－３－カルボニトリルを含む製剤

Assigned to Loxo Oncology Inc · Expires 2022-10-14 · 4y expired

What this patent protects

Patent listed against Retevmo.

Drugs covered by this patent

Patent Metadata

Patent number
JP7153719B2
Jurisdiction
JP
Classification
—
Expires
2022-10-14
Drug substance claim
No
Drug product claim
No
Assignee
Loxo Oncology Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.